Exciva GmbH closed a €51 million (US$59.9 million) Series B to finance a Phase II/III trial of Deraphan, a combination therapy for agitation in Alzheimer’s disease. The Heidelberg‑based neuropsychiatry specialist said funds will support mid‑stage development and enable regulatory interactions for an indication with high unmet need. Investors backed the round amid growing emphasis on behavioral‑symptom treatments in neurodegeneration.